Ipsen sales and marketing update

Ipsen said it will begin resupplying Increlex mecasermin in the U.S. on June 2. The company said it will release one batch in June in collaboration with FDA and expects to release additional lots in the "coming months." The supply interruption began in the U.S. mid-June 2013 and in the rest of the world in 3Q13 due to undisclosed manufacturing issues at the Hopkinton, Mass., facility of Lonza Group Ltd. (SIX:LONN, Basel, Switzerland), which supplies the drug. Ipsen said resupply in the EU and other markets has been effective since December (see BioCentury, Jan. 6). ...